NOLI CAVA: Open Payments
NPI 1265453435 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,810 in 77 payments from 16 companies in 2025. Trend: 2023 $1,728 · 2024 $1,725 · 2025 $1,810
Food & beverage: $1,810
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 27 | $719 |
| Gilead Sciences, Inc. | 10 | $227 |
| Lilly USA, LLC | 12 | $196 |
| Almatica Pharma LLC | 5 | $135 |
| GlaxoSmithKline, LLC. | 5 | $123 |
| Teva Pharmaceuticals USA, Inc. | 4 | $88 |
| PFIZER INC. | 3 | $62 |
| Abbott Laboratories | 2 | $57 |
| Amgen Inc. | 2 | $47 |
| Neurocrine BioSciences, Inc. | 1 | $36 |
Products named: AIRSUPRA, BREZTRI, LOREEV XR, MOUNJARO, FARXIGA, AUSTEDO XR, TRELEGY ELLIPTA, FREESTYLE LIBRE 3.
Industry payments across CA — which companies pay providers there.
